Research Trials

Roger Greenberg, MD, PhD, the Basser Center’s Director of Basic Science and the Director of the new Penn Center for Genome Integrity, discusses the new Center and how its research will apply to hereditary cancer and more.

Kim Reiss Binder, MD, a medical oncologist and clinical researcher with the Basser Center and the University of Pennsylvania, explains ongoing trials and recent advancements related to BRCA-related pancreatic cancer.

Basser Center Executive Director Susan Domchek, MD, discusses the BFOR Study and the importance of genetic testing for hereditary cancer in the Ashkenazi Jewish community.

In the first in an ongoing series of answers to common questions received by the Basser Center, Executive Director Susan Domchek, MD, discusses recent advancements in treatment options for BRCA-related cancers, such as drugs like PARP inhibitors.
 

The Basser Center's 2018 Breakthroughs and Discoveries Panel brought together some of the world's leading experts in genetic research and hereditary cancer.

The Basser Center's internationally recognized experts in cancer genetics, Susan Domchek, MD, and Katherine Nathanson, MD, are working in collaboration with leading experts in the fields of cancer research and genetics in New York, Los Angeles, and Boston to launch the pilot phase of a new, independent research initiative: the BRCA Founder Outreach (BFOR) Study.

A phase II clinical trial that began in August of 2017, “A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation,” is enrolling patients at the Hospital of the University of Pennsylvania.